Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications.

Merola, Joseph F; McInnes, Iain B; Deodhar, Atul A; Dey, Amit K; Adamstein, Nicholas H; Quebe-Fehling, Erhard; Aassi, Maher; Peine, Michael; Mehta, Nehal N

Merola, Joseph F; McInnes, Iain B; Deodhar, Atul A; Dey, Amit K; Adamstein, Nicholas H; Quebe-Fehling, Erhard; Aassi, Maher; Peine, Michael; Mehta, Nehal N.

Afiliação

Merola JF; Brigham and Women's Hospital, Harvard Medical School, Boston, USA.
McInnes IB; University of Glasgow, Glasgow, UK.
Deodhar AA; Oregon Health and Science University, Portland, USA.
Dey AK; Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Adamstein NH; Brigham and Women's Hospital, Boston, MA, USA.
Quebe-Fehling E; Novartis Pharma AG, Basel, Switzerland.
Aassi M; Novartis Pharma AG, Basel, Switzerland.
Peine M; Novartis Pharma AG, Basel, Switzerland.
Mehta NN; Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, 20892, USA. nehal.mehta@nih.gov.

Rheumatol Ther ; 9(3): 935-955, 2022 Jun.

Article em En | MEDLINE | ID: mdl-35305260

Palavras-chave

Axial spondyloarthritis; C-reactive protein; Cardiovascular; Neutrophillymphocyte ratio; Psoriasis; Psoriatic arthritis; Secukinumab; Systemic inflammation

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Rheumatol Ther Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google